Article
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Oncotarget - 29 Dec 2015
Zhang Yi, Yao Ke, Shi Chengcheng, Jiang Yanan, Liu Kangdong, Zhao Song, Chen Hanyong, Reddy Kanamata, Zhang Chengjuan, Chang Xiaoyu, Ryu Joohyun, Bode Ann M, Dong Ziming, Dong Zigang
Abstract excerpt
The epidermal growth factor receptor (EGFR) is known to play a critical role in non-small cell lung cancer(NSCLC). Several EGFR tyrosine kinase inhibitors(TKIs), such as gefitinib, have been used as effective clinical therapies for patients with NSCLC. Unfortunately, acquired resistance to gefitinib commonly occurs after 6-12 months of treatment. The resistance is associated with the appearance of the L858R/T790M...
Topics
- Animals
- Antineoplastic Agents
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Cell Proliferation
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Enzyme Activation
- ErbB Receptors